Who should have genetic testing for the lynch syndrome?

Annals of Internal Medicine

Volumn 155, Issue 2, 2011, Pages 127-128

  Burt, Randall W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ANALYTIC METHOD; CANCER RISK; CANCER SCREENING; CANCER TEST; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENETIC RISK; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MARKOV MODELING ANALYSIS; MICROSATELLITE INSTABILITY; PREMM MODEL; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 79960611444     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-2-201107190-00009     Document Type: Editorial

References (11)

1. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-2058.
2. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424-425.
3. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116:1453-1456.
4. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004;4:153-158.
5. Weissman SM, Bellcross C, Bittner CC, Freivogel ME, Haidle JL, Kaurah P, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome-a review. J Genet Couns. 2011;20:5-19.
6. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer. A cost-effectiveness analysis. Ann Intern Med. 2011; 155:69-79.
7. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009;11:3-14.
8. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93-104.
9. Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer. 2010;9:109-115.
10. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4:9-22.
11. Kastrinos F, Steyerberg EW, Mercado R, Balmaña J, Holter S, Gallinger S, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140:73-81.